TY - JOUR
T1 - Enabling patient-reported outcome measures in clinical trials, exemplified by cardiovascular trials
AU - Coles, Theresa M.
AU - Hernandez, Adrian F.
AU - Reeve, Bryce B.
AU - Cook, Karon
AU - Edwards, Michael C.
AU - Boutin, Marc
AU - Bush, Elizabeth
AU - Degboe, Arnold
AU - Roessig, Lothar
AU - Rudolph, Amy
AU - McNulty, Pauline
AU - Patel, Nikunj
AU - Kay-Mugford, Trish
AU - Vernon, Margaret
AU - Woloschak, Michael
AU - Buchele, Gustavo
AU - Spertus, John A.
AU - Roe, Matthew T.
AU - Bury, Denise
AU - Weinfurt, Kevin
N1 - Funding Information:
TMC reports contracts from FDA and Merck. AFH reports personal fees from Amgen, grants and personal fees from AstraZeneca, personal fees from Boston Scientific, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Bayer, personal fees from Cytokinetics, grants from American Regent, personal fees from Myokardia, personal fees from Eidos, personal fees from Intercept, grants and personal fees from Merck, grants and personal fees from Novartis, personal fees from Relypsa, and grants from Verily. MB reports support from National Health Council Members and Sponsors; the National Health Council membership listing is available at: http://www.nationalhealthcouncil.org/about-nhc/membership-directory . EB is an employee and shareholder of Eli Lilly and Company. AD is a full-time employee of AstraZeneca. LR is an employee of Bayer AG. AR is an employee of Novartis. PM is an employee of Janssen and owns stock in Johnson & Johnson. NP is an employee of AstraZeneca. TK-M is an employee of Novartis. MV is an employee of Evidera. MW is an employee of Sanofi. GB is an employee of Ionis Pharmaceuticals. No other disclosures were reported.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Objectives: There has been limited success in achieving integration of patient-reported outcomes (PROs) in clinical trials. We describe how stakeholders envision a solution to this challenge. Methods: Stakeholders from academia, industry, non-profits, insurers, clinicians, and the Food and Drug Administration convened at a Think Tank meeting funded by the Duke Clinical Research Institute to discuss the challenges of incorporating PROs into clinical trials and how to address those challenges. Using examples from cardiovascular trials, this article describes a potential path forward with a focus on applications in the United States. Results: Think Tank members identified one key challenge: a common understanding of the level of evidence that is necessary to support patient-reported outcome measures (PROMs) in trials. Think Tank participants discussed the possibility of creating general evidentiary standards depending upon contextual factors, but such guidelines could not be feasibly developed because many contextual factors are at play. The attendees posited that a more informative approach to PROM evidentiary standards would be to develop validity arguments akin to courtroom briefs, which would emphasize a compelling rationale (interpretation/use argument) to support a PROM within a specific context. Participants envisioned a future in which validity arguments would be publicly available via a repository, which would be indexed by contextual factors, clinical populations, and types of claims. Conclusions: A publicly available repository would help stakeholders better understand what a community believes constitutes compelling support for a specific PROM in a trial. Our proposed strategy is expected to facilitate the incorporation of PROMs into cardiovascular clinical trials and trials in general.
AB - Objectives: There has been limited success in achieving integration of patient-reported outcomes (PROs) in clinical trials. We describe how stakeholders envision a solution to this challenge. Methods: Stakeholders from academia, industry, non-profits, insurers, clinicians, and the Food and Drug Administration convened at a Think Tank meeting funded by the Duke Clinical Research Institute to discuss the challenges of incorporating PROs into clinical trials and how to address those challenges. Using examples from cardiovascular trials, this article describes a potential path forward with a focus on applications in the United States. Results: Think Tank members identified one key challenge: a common understanding of the level of evidence that is necessary to support patient-reported outcome measures (PROMs) in trials. Think Tank participants discussed the possibility of creating general evidentiary standards depending upon contextual factors, but such guidelines could not be feasibly developed because many contextual factors are at play. The attendees posited that a more informative approach to PROM evidentiary standards would be to develop validity arguments akin to courtroom briefs, which would emphasize a compelling rationale (interpretation/use argument) to support a PROM within a specific context. Participants envisioned a future in which validity arguments would be publicly available via a repository, which would be indexed by contextual factors, clinical populations, and types of claims. Conclusions: A publicly available repository would help stakeholders better understand what a community believes constitutes compelling support for a specific PROM in a trial. Our proposed strategy is expected to facilitate the incorporation of PROMs into cardiovascular clinical trials and trials in general.
KW - Clinical trials
KW - Patient-reported outcome measures
KW - Think Tank meeting results
UR - http://www.scopus.com/inward/record.url?scp=85107965974&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107965974&partnerID=8YFLogxK
U2 - 10.1186/s12955-021-01800-1
DO - 10.1186/s12955-021-01800-1
M3 - Comment/debate
C2 - 34120618
AN - SCOPUS:85107965974
SN - 1477-7525
VL - 19
JO - Health and Quality of Life Outcomes
JF - Health and Quality of Life Outcomes
IS - 1
M1 - 164
ER -